Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
Featured trial
C1071003 MagnetisMM-3

antibody: binding of PF-06863135 to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

refractory multiple myeloma
  • 1 views
  • 18 Oct, 2021
  • 5 locations
None
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.

  • 37 views
  • 29 May, 2021
  • 1 location
None
Dose Exploration Study OF JWCAR129 BCMA-Targeted CART for RRMM

maturation antigen (BCMA), in adult subjects with relapsed and/or refractory multiple myeloma.

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on

  • 0 views
  • 15 Apr, 2021
  • 1 location
None
HB10101 Multiple Myeloma

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma Patients

  • 0 views
  • 03 Feb, 2021
  • 1 location
None
Integrin 7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells

According to the high expression of tumor cell-associated antigen CD138, integrin 7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T

  • 0 views
  • 26 Jan, 2021
  • 3 locations
None
A Single-center Exploratory Clinical Study to Evaluate the Safety Tolerability and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma

This is a prospective, single-arm, single-center, open-label dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCX cells in subjects with relapsed/refractory multiple myeloma

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

  • 0 views
  • 26 Jan, 2021
  • 5 locations
None
Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

  • 0 views
  • 31 May, 2021
  • 1 location
None
Dose Escalation Study of Teclistamab a Humanized BCMA*CD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

estrogen
proteasome inhibitor
multiple myeloma
  • 292 views
  • 13 Oct, 2021
  • 16 locations